JP2003512011A5 - - Google Patents

Info

Publication number

JP2003512011A5

JP2003512011A5 JP2000578351A JP2000578351A JP2003512011A5 JP 2003512011 A5 JP2003512011 A5 JP 2003512011A5 JP 2000578351 A JP2000578351 A JP 2000578351A JP 2000578351 A JP2000578351 A JP 2000578351A JP 2003512011 A5 JP2003512011 A5 JP 2003512011A5

Authority

JP

Japan

Prior art keywords

shows

seq

peptide

domain

amino acid

Prior art date

1999-10-25

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 125000003275 alpha amino acid group Chemical group 0.000 description 28
• 239000000539 dimer Substances 0.000 description 27
• 239000002773 nucleotide Substances 0.000 description 25
• 125000003729 nucleotide group Chemical group 0.000 description 25
• 108090000765 processed proteins & peptides Proteins 0.000 description 25
• 230000004927 fusion Effects 0.000 description 17
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 12
• 150000001875 compounds Chemical class 0.000 description 11
• 239000000203 mixture Substances 0.000 description 10
• 241000699670 Mus sp. Species 0.000 description 8
• 239000005557 antagonist Substances 0.000 description 8
• 108010002352 Interleukin-1 Proteins 0.000 description 5
• 210000004027 cell Anatomy 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 230000015572 biosynthetic process Effects 0.000 description 4
• 238000003776 cleavage reaction Methods 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 230000007017 scission Effects 0.000 description 4
• 108020004414 DNA Proteins 0.000 description 3
• 241000699666 Mus <mouse, genus> Species 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 108090000623 proteins and genes Proteins 0.000 description 3
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
• 102000001554 Hemoglobins Human genes 0.000 description 2
• 108010054147 Hemoglobins Proteins 0.000 description 2
• 229940124761 MMP inhibitor Drugs 0.000 description 2
• 108091028043 Nucleic acid sequence Proteins 0.000 description 2
• 101710113649 Thyroid peroxidase Proteins 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
• 150000001413 amino acids Chemical class 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 238000010586 diagram Methods 0.000 description 2
• 230000006334 disulfide bridging Effects 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• 239000013613 expression plasmid Substances 0.000 description 2
• 238000005534 hematocrit Methods 0.000 description 2
• 239000012535 impurity Substances 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 238000000034 method Methods 0.000 description 2
• 239000000178 monomer Substances 0.000 description 2
• 239000013631 noncovalent dimer Substances 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 2
• 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 description 1
• 101000694103 Homo sapiens Thyroid peroxidase Proteins 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 102000053400 human TPO Human genes 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 150000007523 nucleic acids Chemical class 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 108010002543 polyethylene glycol-recombinant human megakaryocyte growth and development factor Proteins 0.000 description 1
• 238000006268 reductive amination reaction Methods 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1